The ARSP EGASP Study Group contributed to a recent multi-country study evaluating zoliflodacin, a new drug candidate for gonorrhea. The study tested 2,993 Neisseria gonorrhoeae isolates collected from eight countries between 2021 and 2024, showing strong in-vitro activity including against strains resistant to ceftriaxone and azithromycin. These results support further clinical development of zoliflodacin while emphasizing the need for continued global resistance monitoring.

Click this link for the full-text article: https://www.sciencedirect.com/science/article/pii/S2772707625000591